January 18, 2024 5pm GMT
Ian Tannock, MD, PhD (Chair)
Discussants:
Richard Sullivan, MD, PhD
Samra Turajlic MD PhD
Andrew Reynolds PhD
Steve Wedge PhD
Jack Scannell, DPhil
«The current privileged focus on biopharmaceuticals is not a long-term, cost-effective approach to cancer control policy, unless it is complemented with public health strategies for cancer prevention»
This statement, published in a recent Lancet Oncology Commission paper, will be discussed by a panel with expertise in cancer policy, basic cancer bioscience and the treatment of cancer, strategies in the pharmaceutical industry for both prevention and treatment, and expertise in the analysis of the economics of the drug industry. Are biopharmaceuticals a long-term approach to reduce cancer mortality? Is basic bioscience research too strongly focused on supporting therapeutic strategies to reduce post-diagnosis cancer mortality? How can the basic bioscience community and the pharmaceutical industry compliment public health strategies for early detection and cancer prevention?